Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Bevacizumab and Cyclophosphamide in Recurrent Mullerian Cancer
NCT00856180Phase 2
Key facts
- Status
- Completed
- Start
- Feb 2009
- Primary completion
- Apr 2010
- Countries
- 1
- Sponsor
- Dana-Farber Cancer Institute
- Modality
- Monoclonal Antibodies
- Drugs
- bevacizumab
- Conditions
- ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Therapy Completion Rate at 3 months and Grade 3-5 Gastrointestinal Perforation at 3 months. Started Feb 2009; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Sequential Blockade
Bevacizumab followed by Bevacizumab + Cyclophosphamide
03
Who it enrols
Patients with recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer who have failed a platinum-based regimen, have measurable disease, ECOG 0-1, and no bowel obstruction or history of GI perforation.
04
Endpoints
Primary
Therapy Completion Rate
Grade 3-5 Gastrointestinal Perforation
Secondary
Clinical Benefit Response Rate
Progression-Free Survival
Overall Survival
Beyond the preview
Go deeper on NCT00856180.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856180.